Robert Burns
Welcome to our next fireside chat. I am Robert Burns, the Managing Director and Senior Biotech Analyst at H.C.
Wainwright. I am joined today by J.
Jean Cui, the CEO of the newly formed BlossomHill, which just IPO'd. Jean, thank you for joining us today.
Jean Cui
Thank you, Robert, for having us here.
Robert Burns
No problem. I guess let's start from the 10,000-foot view.
Considering that you just IPO'd in August, maybe for those who may be unfamiliar with the BlossomHill story, tell us a little bit about the company and its pipeline.
Jean Cui
Thank you. I'm J.
Jean Cui, and the scientific founder, and also President and CEO of BlossomHill Therapeutics. BlossomHill Therapeutics was founded in June 2020, just in the middle of the pandemic, COVID-19 pandemic.
Stay at home, and have, kind of really extra time, and to really think about the science. Because every company I've founded, I really need to have the directions, and what exactly we should do, and what is our capability be able to solve and answer, high unmet medical needs, especially needs the innovation of the chemistry.
By training I'm the chemist, and so this is why, and, kind of we really want to find the clinical unmet medical need needs the chemistry innovation. With the strong support of the leading investors, we have built, very strong leadership team, and also the advanced two molecules, and macrocyclic molecule, and into clinic, and also one, and in the IND-enabling studies.
As the chemist, as the founder, and we have built up all of our pipelines from the ground up, and from identify unmet medical needs, and so here is the summary, the BlossomHill way to deliver our candidates, and identify unmet medical need for patients. This is definitely, and we want to really kind of identify something, and might be stuck, kind of quite difficult in the field.
Then using the, analysis, and, what is the issue there, and how we can solve the issues from which angle. The different part, we are to do the, kind of do the structure-based design.
However, and different from structure-based design, here we really focus on the protein dynamics, because in the disease state, and the protein probably stay in the different conformation, and which state is better to overcome. The first line of therapy requirement probably is different compared to resistant setting there.
Then, lead optimization, and to identify, and the clinical, and the candidates there. This is, and our pipeline, and we have only EGFR inhibitor, and this is a macrocyclic molecule.
We'll talk more about this molecule. It is, and have the broad inhibition against the classical EGFR mutation, atypical mutation, and also, most important, be able to tackle all of these resistant mutations, and currently in the late expansion stage, and we hope to have for the end-of-Phase 1 meeting in the Q4 2026.
The CLK inhibitor is a target and broad resistance mechanism associate cancer treatment. We know the cancer treatment, the ultimate goal is to shrink the tumor, and then shrink the tumor will generate common resistance mechanism, and the escape, and for the survival, and also, most important, DNA damage repair pathway.
CLK is moderate and serine/arginine-rich splicing protein, and then leading to the modulate, and the end result is modulate DNA repair pathway, and also survival and balance there. This project currently in the dose escalation in both monotherapy and also in combination with venetoclax.
Then our pan-KRAS inhibitor, and have the novel and chemicals design, and leading to very distinctly different profile, and with a pseudo-irreversible characteristic. This molecule in the late IND-enabling studies, and we plan for IND submission in the first half and the first quarter 2027.
Robert Burns
Thanks, Jean. Similar to what we saw with your prior company, Turning Point Therapeutics, there seems to be a recurring theme here when we look at the approach you took when designing BlossomHill's drug candidates.
In particular, two of your two of the three of your assets are macrocyclic-based structures. Maybe, help investors who might not be as scientifically inclined understand the rationale between this and the advantages that macrocyclic-based inhibitors actually possess over non-macrocyclic-based ones.
Jean Cui
Great question. That is, kind of the my first design for macrocyclic, and from lorlatinib, and later, and repotrectinib.
Macrocyclic design is a common tool for medicinal chemists to solve the issues. Quite often, by the end, macrocyclic, and quite often will deliver, and super cell potency, and good drug-like properties, and also, kind of the good safety profile.
The bottom line, macrocyclic is rigidify the conformation to have the precise interaction with the protein there. Kind of the not all of the target and will suitable for the macrocyclic design, such as KRAS and Switch II pocket inhibitor may not good for the macrocyclic.
However, when we work on the kinase, and especially for resistant patient population, and this is really kind of the tool we have to use. When we're talking about the resistant, and kind, the kinase already, and the pathway is highly activated, and, develop resistant as a later generation, and need to overcome the resistant, that's its number one requirement.
Also the molecule need to be also super better potency against the primary mutation. We know the different subclones, the primary and mutation still exists, co-existed, either cis or trans, and with resistant mutation.
Therefore, the molecule need to be significantly better than previous generation, be able to overcome all of this resistant. Also, kind of to avoid other and mutations.
That is why and for the kinase and next generation, when we design the molecule target ATP center need to achieve the super potency, the macrocyclic is the, the best tool to use. As you can see, I designed both lorlatinib, repotrectinib as the macrocyclic, you can see and the small cycle the macrocyclic there, and be able to achieve both super cell potency against the primary mutation, and also, most important, is resistant mutation, and good PK properties enables the molecule to overcome resistant in the later line, and also when it use to the front line, and achieve make the treatment outcome significant leap, like lorlatinib using to the front line, and it is improved the PFS from original, and crizotinib less than one year to over seven years.
This is what we target to. Then, kind of during the pandemic, I'm thinking about the EGFR.
EGFR, and C797S, already three-generation EGFR inhibitor has been approved, and, Tagrisso is the third-generation, covalent, irreversible molecule. This one, and, here it shows, Tagrisso, the structure there.
The osimertinib is the chemical structure is not really the true binding for the EGFR protein there. Without the covalent binding part I highlight there is a blue color to form the covalent binding there, and without covalent, that will be sub-micromolar activity there.
To, kind of overcome this C797S, the molecule design have to be a non-covalent molecule, and also need to capture the true and binding the protein characteristic of the EGFR. We designed a novel macrocyclic structure, and after, kind of this structure at design, and as you compare the first-generation and third-generation, and this structure not share any of the commonality with them.
After lead optimization, we are able to achieve the super cell potency, sub-nanomolar, against the classic atypical mutation, the brown color, and that is a compound resistant mutation. As you can see, it is equipotent against them.
This is very important when we use in the later line there. The molecule is also 10-fold more potent compared to covalent molecule osimertinib there.
This is also the only molecule and be able to achieve this broader activity against both the primary and resistant mutation, and have great selectivity window over the wild-type EGFR.
Robert Burns
Awesome, thank you for that background. With that as the backdrop here, you presented some data at WCLC literally a few hours ago.
Maybe you could walk us through that data for your lead agent, BH-30643, and what stood out to you most from that dataset? Yeah.
Jean Cui
Kind of for people don't know the data, let me kind of present the here is, kind of updated in the WCLC, and we updated our Phase 1 data for patients with C797S-resistant population. As you remember, we first present the data at ASCO 2026, and with patient, efficacy evaluable patient, and it's about 34 patients there.
In the WCLC, and our data cut is May 12, 2026, with efficacy follow-up until August 10, 2026, and a median follow-up time is 6.9 months. This time, we present 40 patients, and is efficacy evaluable patient, and objective response rate and is 45%.
Within that is 17 patients is a confirmed response. We have one patient is unconfirmed response ongoing, waiting to be confirmed.
Disease control rate and is 88%. That is kind of the, and the patient, as you can see, the with and without the T790M, and shows the great efficacy there.
Also, and with the patient treated without chemotherapy, and ORR is 53%, and with the chemotherapy is 38% there. The patient, and actually the and it is a highly kind of brain penetrator, about over 50% patients have the brain and metastasis there.
The data also kind of very important update, and it is, kind of durability. This is the very first, and the molecule demonstrated durable response against C797S.
Here, and, with 6.9 months and follow-up, and 63% patients still remain on study. As you can see, we have three patients treatment and already beyond one year.
That is, kind of everybody and waiting for the data to see the C797S still oncogene driver and be able to achieve durable response. At the same time, we also update the safety profile at efficacy level, and in the expansion dose level, and we have three dose levels in the expansion cohort at 40 mg, and 50 mg, and also 60 mg BID dose level, and 174 patients there.
As you can see, the dose reduction rate is low, is 9%, and also discontinuation rate is 3%, and related treatment-related AE there. EGFR wild-type related AEs and mainly and is Grade 1.
You can see both the rash, and also diarrhea, and it is most of them is Grade 1. The molecule and also and it is have the rare pneumonitis, and only about 1%.
We only have two cases there, and possibly related molecule. No clinically significant treatment-related cardio effects, such as QT, QTc prolongation.
Among the, all of the AEs, the most common AE and TRAE is bilirubin increase. This bilirubin increase, and it's due to 643 inhibits the transporter UGT1A1.
The transport UGT1A1 enzyme responsible for the glucuronidation of the bilirubin. Therefore, what we observed, the bilirubin increase mainly is unconjugated, and no symptom associate with patient, and quite often no need for the dose adjustment.
Kind of Grade 3 and is about 7% in the among the 174 patients. We also observed some of ALT, AST elevation, and it is in about 7% for the ALT.
These two, ALT and AST, and also compared to the bilirubin have the different mechanism. Bilirubin increase quite often is onset quick, and when we reach steady state, and it is, we can observe that.
Then, and liver enzyme increase, and quite often kick in and in about six six weeks there. This is two different mechanism, and no case and meets the Hy's Law there.
Yeah.
Robert Burns
Thank you for that. One of the things that we're also seeing within the field is from a competitive landscape perspective, obviously, we've seen some data from Hansoh Pharma, Dizal, as well as Voronoi.
How are you interpreting those competitive datasets, and where do you think 30643 is potentially differentiated relative to those competitor agents?
Jean Cui
Kind of the we are glad to see the three company, and, try to solve the C797S issue there. C797S first reported, back to 10 years ago, 2015, and now we finally see is able to overcome and this resistant.
All of their molecule is in the early Phase 1 stage, and we don't know too much about the structure of the other three molecule. Based on the Voronoi molecule, and it is claimed, and based on the corporate presentation, and it is a first generation modification, and it is not able to overcome and T790M resistant.
Then for other two, we don't know exact structure based on the preclinical data, and likely, kind of look like, and the potency against the primary mutation may be, kind of not equipotent compared to osimertinib or less potent. We do believe it is very important, and the, kind of the next generation needs to be significantly more potent compared to previous generation osimertinib there.
We do compare with the public information, we do believe, and 643 is the only molecule have 10-fold more potent compared to osimertinib, equipotent against all of these resistant mutation, and also atypical mutation. It also had good activity against exon 20, good selectivity window.
Since it is, macrocyclic design, and we have the very good PK exposure level, and make the clinical coverage, and probably give the, great advantage, and, to give the, as you can see, the durable response there.
Robert Burns
Awesome, thank you for that. Why don't we shift gears now to a few of the other assets in your pipeline.
I wanted to focus on your RAS inhibitor, 502184. Obviously, we saw recently daraxonrasib being FDA approved or gaining FDA approval in metastatic PDAC, and, there are a number of other pan-RAS or pan-KRAS approaches that are moving through development.
What specifically differentiates your approach, and how are you thinking about the development strategy for this agent?
Jean Cui
The pan-RAS inhibitor really revolution, and, in the PDAC. We also know the history of the targeted therapy.
The first one, and represent the start of the new era. Then, for the next and late comer, and need to really focus on the improvement, how we can make the treatment go to the next level, and both on safety, and most important, and is efficacy, and durability, how we are can be able to achieve the treatment beyond one year, and two year, and then, the time treatment duration there.
The, and our molecule, and 501284, is a novel chemical structure, and designed as a Switch II inhibitor. I want to have a little bit background regarding to the distinction, kind of different from Switch II inhibitor compared to the tri-complex molecule.
The tri-complex molecule, we know it's on-state inhibitor, and it is block and using steric hindrance from the cyclophilin block, and RAF and effector coming interact with the KRAS. However, this tri-complex also facilitate, and the GTP and hydrolysis back to the GDP.
Then GDP will cycle back and to the GTP. That means it is not shut down the cycling.
With the cycling continue, and that would be the issue for the durability. Then the for the Switch II pocket inhibitor, it is rigidify the KRAS protein, makes the surface is no longer to be flexible enough to have tight interaction with effector such as RAF, all the, kind of the GTP, that's GEF, and SOS1, this kind of effector.
It is completely shut down the cycling there. We know the KRAS G12C covalent molecule, the next generation achieved the progression-free surviving time more than one year.
To leverage to, this success, we design our molecule as a pseudo-irreversible molecule be able to completely shut down and RAS and RAF interactions, and achieve the significantly deeper and longer and in the in vivo study compared to tri-complex molecule.
Robert Burns
Awesome, thank you for that. One of the potential interesting aspects of BlossomHill is that, you've got multiple programs in-house, under one roof, and there's the potential for internal combinations, at least in my opinion.
Where do you see opportunities to combine your pan-KRAS agent with other agents within the BlossomHill portfolio, and what combinations do you find most compelling?
Jean Cui
Internal combination, and definitely, and our CLK inhibitor, and it is a target, kind of general and resistance mechanism, and especially apoptosis pathway and DNA repair pathway. It is, kind of in our preclinical data, and it shows the great synergy when it's combined with EGFR inhibitor, or combined with the KRAS inhibitor.
For people don't know the splicing, and, kind of the splicing and modulation, and you probably very familiar with recent exciting taste PRMT5 and inhibitor combination with the KRAS in a great synergy there. Modulate the splicing in certain point, and have the similar and outcome compared to PRMT5.
The preclinical data is very exciting, yeah.
Robert Burns
I'm pretty sure you're referring to the Tango dataset, where, they combined their PRMT5 with the pan-KRAS daraxonrasib. Have you shown any data preclinically that compared the Tango agent with daraxonrasib compared to your CLK inhibitor plus your pan-KRAS inhibitor?
Jean Cui
Yes, and this is, great question, and this is really experiment ongoing. We hope we will present more data at the coming, and next year AACR.
Yeah.
Robert Burns
Oh, perfect, perfect. Running up on time, one last question, if I may.
Maybe to wrap things up, as we look towards the next 12 to 18 months, what sort of key catalysts can investors look forward to?
Jean Cui
For our only EGFR project, and the immediate and catalyst and milestone, and is the end-of-Phase 1 meeting. That is coming and Q4 2026, and that we will identify and got agreement with FDA on the RP2D selection, and also the pivotal and Phase 2 design, and for C797S-resistant population.
Then next year, and 2027 first half, we'll present more data on C797S, especially, and we hope we can read out the durability and for this. We also present some data before, and regarding naive patient, and the second half 2027, we'll present more data on the naive patient, and hope we can read out at least one-year durability for TKI-naive patient population.
Also, and we already start and combination with chemotherapy, and we will present second half 2027, and we will present initial Phase 1 data combination with chemotherapy 643, and in terms of safety and also anti-tumor activities.
Robert Burns
Awesome, thank you, Jean, for joining us today. I'm looking forward to all the datasets that are going to be coming out from BlossomHill.
Jean Cui
Thank you.